Trump and pharma execs to discuss progress on COVID-19 cure
The White House task force and the US President will meet drug makers this afternoon to discuss "progress on a vaccine and cure".
In an early morning Tweet, US President Trump said he will be meeting with major pharmaceutical companies today at the White House to discuss "progress on a vaccine and cure" for coronavirus (COVID-19) outbreak. This statement comes after the infection claimed the country's second victim during the weekend.
Although Trump provided no further information or details, including clues as to which companies would be attending, it has been reported that executives from Sanofi, Johnson & Johnson, GSK and Pfizer will be appearing at this afternoon's meeting.
The head of the infectious diseases unit at the US National Institutes of Health, Dr Anthony Fauci, said he was concerned the number of US cases could jump in the coming weeks.
“When you have a number of cases that you’ve identified and they’ve been in the community for a while, you’re going to wind up seeing a lot more cases than you would have predicted,” he told CNN in an interview on Monday. He continued to explain his concern that "we’re going to see a lot more community-related cases" during the next few weeks.
Meanwhile, on the other side of the Atlantic, Prime Minister Boris Johnson, has said the spread of coronavirus is a "problem that is likely to become more significant".
Johnson's comment comes as the number of cases in the UK rises to 40. The prime minister has also chaired a meeting today of the government's emergency committee, Cobra, to agree a plan to tackle the crisis.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.